JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Tadalafil is a research compound studied in cell-based assay formats for its selective PDE5 enzyme inhibition, cGMP pathway modulation, and PKG activation. Published in vitro research characterizes its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
Tadalafil acts via selective phosphodiesterase type 5 (PDE5) enzyme inhibition, resulting in cyclic guanosine monophosphate (cGMP) pathway modulation and protein kinase G (PKG) activation. Competitive radioligand binding studies demonstrate high-affinity interactions with the PDE5 catalytic domain, with Ki values typically ranging from 0.94 to 5.0 nM in isolated enzyme preparations.
The compound exhibits selective binding characteristics across phosphodiesterase enzyme subtypes. In vitro enzyme kinetic studies reveal IC50 values of approximately 1.8 nM for PDE5, while demonstrating significantly lower affinity for related phosphodiesterases including PDE1, PDE2, PDE3, PDE4, and PDE6. This selectivity profile supports its utility in research applications requiring specific PDE5 pathway interrogation.
Kinetic analysis in cell-free systems demonstrates competitive inhibition patterns with respect to cGMP substrate binding. Lineweaver-Burk plot analysis confirms competitive kinetics, with increased apparent Km values in the presence of tadalafil while Vmax remains unchanged. The reversible nature of binding allows for washout experiments in cell culture models to assess pathway recovery dynamics.
Binding affinity studies using radiolabeled tadalafil derivatives in membrane preparations from PDE5-expressing cell lines reveal saturable binding with Bmax values correlating with PDE5 expression levels. Scatchard analysis confirms single-site binding characteristics with Hill coefficients approaching unity, indicating non-cooperative binding interactions.
Primary vascular smooth muscle cell cultures provide robust model systems for investigating tadalafil's effects on cGMP signaling cascades. In these preparations, PDE5 expression can be modulated through passage number, serum conditions, and phenotypic state manipulation. Contractile phenotype cells typically express higher baseline PDE5 levels compared to synthetic phenotype cultures.
Cyclic nucleotide measurements using enzyme immunoassays demonstrate dose-dependent cGMP accumulation following tadalafil treatment in the presence of nitric oxide donors or natriuretic peptides. EC50 values for cGMP elevation typically range from 10-100 nM depending on cell passage, culture conditions, and co-stimulatory factors.
Human umbilical vein endothelial cells (HUVECs) and other endothelial cell lines express functional PDE5 and serve as relevant models for investigating downstream signaling events. Calcium mobilization studies using fluorescent indicators reveal tadalafil's modulatory effects on store-operated calcium entry and calcium-activated potassium channel function.
Protein kinase G activation can be assessed through substrate phosphorylation assays, including vasodilator-stimulated phosphoprotein (VASP) phosphorylation at Ser239. Time-course studies demonstrate rapid PKG activation within 5-15 minutes of tadalafil exposure in stimulated cells.
Cell uptake studies using radiolabeled compounds demonstrate rapid cellular accumulation with apparent steady-state distribution achieved within 30-60 minutes. Efflux studies reveal relatively slow clearance kinetics, consistent with the compound's lipophilic properties and potential for intracellular sequestration.
Metabolic stability assessments in hepatocyte cultures and microsomal preparations indicate primary metabolism through CYP3A4-mediated pathways. The formation of des-methylated and hydroxylated metabolites can be monitored using liquid chromatography-mass spectrometry approaches.
Standard phosphodiesterase activity assays employ tritiated cGMP substrates with product separation through ion-exchange chromatography or precipitation methods. Optimal buffer conditions typically include 50 mM Tris-HCl (pH 7.4), 8.3 mM MgCl2, and 1.7 mM EGTA for maximal enzyme activity.
High-throughput screening adaptations utilize fluorescence polarization or fluorescent substrate analogs for automated compound screening. These formats enable rapid assessment of binding affinity and functional activity across compound libraries.
Tadalafil represents a valuable pharmacological tool for investigating PDE5-mediated signaling pathways in cellular model systems. Its selectivity profile, well-characterized binding kinetics, and robust functional activity make it suitable for mechanistic studies of cGMP signaling cascades. The compound's stability in cell culture conditions and defined pharmacokinetic properties support its application in time-course studies and combination experiments with other signaling pathway modulators.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.